Xbrane Biopharma AB
STO:XBRANE

Watchlist Manager
Xbrane Biopharma AB Logo
Xbrane Biopharma AB
STO:XBRANE
Watchlist
Price: 11.54 SEK -3.83%
Market Cap: 237.8m SEK

Intrinsic Value

The intrinsic value of one XBRANE stock under the Base Case scenario is 127.96 SEK. Compared to the current market price of 11.54 SEK, Xbrane Biopharma AB is Undervalued by 91%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

XBRANE Intrinsic Value
127.96 SEK
Undervaluation 91%
Intrinsic Value
Price
Worst Case
Base Case
Best Case
Compare XBRANE to

Fundamental Analysis

Company Overview
Loading...
Economic Moat
Loading...
Earnings Call
Loading...
Management
Loading...
Contacts
Loading...
How do you feel about XBRANE?
Bearish
Neutral
Bullish
Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Xbrane Biopharma AB

Current Assets 397.5m
Cash & Short-Term Investments 93.6m
Receivables 9.4m
Other Current Assets 294.5m
Non-Current Assets 304m
PP&E 86k
Intangibles 303.9m
Current Liabilities 114.4m
Accounts Payable 39.7m
Accrued Liabilities 73.4m
Other Current Liabilities 1.4m
Non-Current Liabilities -1k
Other Non-Current Liabilities -1k
Efficiency

Free Cash Flow Analysis
Xbrane Biopharma AB

Last Value
3-Years Average
FCF Margin
Conversion Rate

Earnings Waterfall
Xbrane Biopharma AB

Revenue
209.1m SEK
Cost of Revenue
-60.1m SEK
Gross Profit
149m SEK
Operating Expenses
-184.3m SEK
Operating Income
-35.3m SEK
Other Expenses
135.8m SEK
Net Income
100.5m SEK
Fundamental Scores

XBRANE Profitability Score
Profitability Due Diligence

Xbrane Biopharma AB's profitability score is 40/100. The higher the profitability score, the more profitable the company is.

ROIC is Increasing
ROE is Increasing
Exceptional Net Margin
Exceptional Gross Margin
40/100
Profitability
Score

Xbrane Biopharma AB's profitability score is 40/100. The higher the profitability score, the more profitable the company is.

XBRANE Solvency Score
Solvency Due Diligence

Xbrane Biopharma AB's solvency score is 64/100. The higher the solvency score, the more solvent the company is.

Long-Term Solvency
Low D/E
Short-Term Solvency
Low Altman Z-Score
64/100
Solvency
Score

Xbrane Biopharma AB's solvency score is 64/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

XBRANE Price Targets Summary
Xbrane Biopharma AB

Wall Street analysts forecast XBRANE stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for XBRANE is 63.75 SEK with a low forecast of 63.13 SEK and a high forecast of 65.63 SEK.

Lowest
Price Target
63.13 SEK
447% Upside
Average
Price Target
63.75 SEK
452% Upside
Highest
Price Target
65.63 SEK
469% Upside
View Analyst Estimates
View Analyst Estimates

Dividends

Xbrane Biopharma AB
does not pay dividends
Shareholder Yield

Current shareholder yield for XBRANE is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Competitive Landscape

Company Market Cap Intrinsic Valuation Profitability Solvency Price Change
1Y 3Y 5Y